Pfizer's $43B Seagen deal strengthens its oncology portfolio, offsets patent cliffs, and offers 70%+ upside potential. See ...

Gain insight on Centene, China’s pharmaceutical sector and more in the latest Market Talks covering the Health Care sector.

While its shares have been lagging the market significantly, that could change in the next decade as financial results ...

Healthcare chief financial officers are shifting their strategic focus toward managing external disruptions, according to ...

Top experts from Amgen, CBIZ & Intrepid discuss 2025 trends in healthcare, biotech, and life sciences. Explore key insights ...

Inaugural 'Innovation Catalyst' event empowers innovators at UConn Health to transform their exciting research ideas into ...

Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same ...

Morgan Stanley finds itself under the scrutinizing eye of FINRA over its client vetting procedures. The watchdog is probing ...

IPG is pretty much holding it together as it waits to complete its merger with Omnicom, reporting a 3.5% decline in organic ...

Pfizer is cutting costs, growing its core business, and trading at a deep discount despite looming patent losses and COVID ...

Industry-Wide Tariffs Loom Over the Healthcare Sector. Here Are 2 Stocks That Can Weather the Storm.

U.S. Health Secretary Robert F. Kennedy Jr., a long-time vaccine skeptic, has been making sweeping changes to reshape vaccine, food and medicine policies.